GI Innovation begins prostate cancer trial with J&J drug
South Korean biotech firm GI Innovation has administered the first dose in a global clinical trial combining its experimental immunotherapy GI-102 with Johnson & Johnson's prostate cancer drug candidate pasritamig, marking a new step in its efforts …